Expression and genetic analysis of transporter associated with antigen processing in cervical carcinoma

Gynecologic Oncology

Volumn 105, Issue 3, 2007, Pages 593-599

  Vermeulen, Christine F W ^a   Jordanova, Ekaterina S ^a   ter Haar, Natalja T ^a   Kolkman Uljee, Sandra M ^a   de Miranda, Noel F ^a   Ferrone, Soldano ^b   Peters, Alexander A W ^a   Fleuren, Gert Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cervical cancer; HLA class I; LOH; Mutation; TAP

Indexed keywords

BETA 2 MICROGLOBULIN; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA C ANTIGEN; PARAFFIN; PROTEIN ANTIBODY; TAP1 ANTIBODY; TAP2 ANTIBODY; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ANTIGEN EXPRESSION; ARTICLE; CELL SELECTION; CHROMOSOME 6P; CONTROLLED STUDY; CORRELATION ANALYSIS; EXON; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; STAINING; TUMOR CELL; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

ATP-BINDING CASSETTE TRANSPORTERS; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA MUTATIONAL ANALYSIS; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; NEOPLASM STAGING; PARAFFIN EMBEDDING; UTERINE CERVICAL NEOPLASMS;

EID: 34248355211     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.02.016     Document Type: Article

References (43)

1. Garcia-Lora A., Algarra I., Collado A., and Garrido F. Tumor immunology, vaccination and escape strategies. Eur. J. Immunogenet. 30 (2003) 177-183
2. Pamer E., and Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol. 16 (1998) 323-358
3. D'Urso C.M., Wang Z.G., Cao Y., Tatake R., Zeff R.A., and Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J. Clin. Invest. 87 (1991) 284-292
4. Townsend A., Elliott T., Cerundolo V., Foster L., Barber B., and Tse A. Assembly of MHC class I molecules analyzed in vitro. Cell 62 (1990) 285-295
5. Sadasivan B., Lehner P., Ortmann B., Spies T., and Cresswell P. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 5 (1996) 103-114
6. Ortmann B., Copeman J., Lehner P.J., Sadacivan B., Herberg J.A., Gandea A.G., et al. A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science 277 (1997) 1306-1309
7. Hughes E.A., and Cresswell P. The thiol oxidoreductase ERp57 is a component of the MHC class I peptide-loading complex. Curr. Biol. 8 (1998) 709-712
8. Van Kaer L. Major histocompatibility complex class I-restricted antigen processing and presentation. Tissue Antigens 60 (2002) 1-9
9. Seliger B., Maeurer M.J., and Ferrone S. TAP off-tumors on. Immunol. Today 18 (1997) 292-299
10. Seliger B., Maeurer M.J., and Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21 (2000) 455-464
11. Atkins D., Ferrone S., Schmahl G.E., Storkel S., and Seliger B. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?. J. Urol. 171 (2004) 885-889
12. Raffaghello L., Prigione I., Bocca P., Morandi F., Camoriano M., Gambini C., et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 24 (2005) 4634-4644
13. Seliger B., Ritz U., Abele R., Bock M., Tampe R., Sutter G., et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res. 61 (2001) 8647-8650
14. Yang T.Y., McNally B.A., Ferrone S., Liu Y., and Zheng P. A single-nucleotide deletion leads to rapid degradation of TAP-1 mRNA in a melanoma cell line. J. Biol. Chem. 278 (2003) 15291-15296
15. Kloor M., Becker C., Benner A., Woerner S.M., Gebert J., Ferrone S., et al. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res. 65 (2005) 6418-6424
16. Seliger B., Atkins D., Bock M., Ritz U., Ferrone S., Huber S., et al. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin. Cancer Res. 9 (2003) 1721-1727
17. Romero J.M., Jimenez P., Cabrera T., Cozar J.M., Pedrinaci S., Tallada M., et al. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta 2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int. J. Cancer 113 (2005) 605-610
18. Connor M.E., and Stern P.L. Loss of MHC class-I expression in cervical carcinomas. Int. J. Cancer 46 (1990) 1029-1034
19. Cromme F.V., Meijer C.J., Snijders P.J., Uyterlinde A., Kenemans P., Helmerhorst T., et al. Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. Br. J. Cancer 67 (1993) 1372-1380
20. Glew S., Connor M., Snijders P., Stanbridge C., Buckley C., Walboomers J., et al. HLA expression in pre-invasive cervical neoplasia in relation to human papilloma virus infection. Eur. J. Cancer 29a (1993) 1963-1970
21. Bontkes H.J., Walboomers J.M., Meijer C.J., Helmerhorst T.J., and Stern P.L. Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet 351 (1998) 187-188
22. Koopman L.A., Corver W.E., Van der Slik A.R., Giphart M.J., and Fleuren G.J. Multiple genetic alterations cause frequent and heterogeneous HLA class I antigen loss in cervical cancer. J. Exp. Med. 191 (2000) 961-976
23. Vermeulen C., Jordanova E., Zomerdijk-Nooijen Y., ter Haar N., Peters A., and Fleuren G.J. Frequent HLA Class I loss is an early event in cervical carcinogenesis. Hum. Immunol. 66 (2005) 1167-1173
24. Cromme F.V., Airey J., Heemels M.T., Ploeg H., Keating P., Stern P., et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179 (1994) 335-340
25. Brady C.S., Bartholomew J.S., Burt D.J., Duggan-Keen M.F., Glenville S., Telford N., et al. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 55 (2000) 401
26. Keating P.J., Cromme F.V., Duggan-Keen M., Snijders P.J., Walboomers J.M., Hunter R.D., et al. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br. J. Cancer 72 (1995) 405-411
27. Ritz U., Momburg F., Pilch H., Huber C., Maeurer M.J., and Seliger B. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int. J. Oncol. 19 (2001) 1211-1220
28. Fowler N.L., and Frazer I.H. Mutations in TAP genes are common in cervical carcinomas. Gynecol. Oncol. 92 (2004) 914-921
29. Krul E., Kersemaekers A., Zomerdijk-Nooyen Y., Cornelisse C., Peters L., and Fleuren G.J. Different profiles of allelic losses in cervical carcinoma cases in Surinam and the Netherlands. Cancer 86 (1999) 997-1004
30. Hazelbag S., Gorter A., Kenter G., van den Broek L., and Fleuren G.J. Transforming growth factor beta1 induces tumor stroma and reduces tumor infiltrate in cervical cancer. Hum. Pathol. 33 (2002) 1193-1199
31. Stam N.J., Spits H., and Ploegh H.L. Monoclonal-antibodies raised against denatured HLA-B locus heavy-chains permit biochemical-characterization of certain HLA-C locus products. J. Immunol. 137 (1986) 2299-2306
32. Sernee M.F., Ploegh H.L., and Schust D.J. Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol. Immunol. 35 (1998) 177-188
33. Perosa F., Luccarelli G., Prete M., Favoino E., Ferrone S., and Dammacco F. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J. Immunol. 171 (2003) 1918-1926
34. Ruiter D.J., Ferrier C.M., van Muijen G.N., Henzen-Logmans S.C., Kennedy S., Kramer M.D., et al. Quality control of immunohistochemical evaluation of tumor associated plasminogen activators and related components. Eur. J. Cancer 34 (1998) 1334-1340
35. Corver W.E., Ter Haar N.T., Dreef E.J., Miranda N.F., Prins F.A., Jordanova E.S., et al. High-resolution multi-parameter DNA flow cytometry enables detection of tumour and stromal cell subpopulations in paraffin-embedded tissues. J. Pathol. 206 (2005) 233-241
36. Vanmuijen G., Ruiter D.J., and Warnaar S.O. Coexpression of intermediate filament polypeptides in human-fetal and adult tissues. Lab. Invest. 57 (1987) 359-369
37. Cleton-Jansen A.M., Callen D.F., Seshadri R., Goldup S., Mccallum B., Crawford J., et al. Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. Cancer Res. 61 (2001) 1171-1177
38. Haven C.J., van Puijenbroek M., Karperien M., Fleuren G.J., and Morreau H. Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J. Pathol. 202 (2004) 86-94
39. Mungall A.J., Palmer S.A., Sims S.K., Ashurst J.L., Wilming L., Jones M.C., et al. The DNA sequence and analysis of human chromosome 6. Nature 425 (2003) 805-811
40. dela Salle H., Houssaint E., Peyrat M.A., Arnold D., Salamero J., Pinczon D., et al. Human peptide transporter deficiency-importance of HLA-B in the presentation of TAP-independent EBV antigens. J. Immunol. 158 (1997) 4555-4563
41. Fuchs I.B., Lichtenegger W., Buehler H., Henrich W., Stein H., Kleine-Tebbe A., et al. The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res. 22 (2002) 3415-3419
42. Jordanova E.S., Corver W.E., Vonk M., Leers M.P., Riemersma S.A., Schuuring E., et al. Flow cytometric sorting of paraffin-embedded tumor tissues considerably improves molecular genetic analysis. Am. J. Clin. Pathol. 120 (2003) 327-334
43. Jordanova E.S., Philippo K., Giphart M.J., Schuuring E., and Kluin P.M. Mutations in he HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma. Immunogenetics 55 (2003) 203-209